We tested whether lesogaberan alone or in combination with an antigen-specific immunotherapy (proinsulin/alum immunization) or an immunodepletive therapy (anti-CD3) could modulate the progression of T1D in newly and severely diabetic NOD mice. The gene discussed is INS; the disease is type 1 diabetes mellitus.